Heron Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Heron Therapeutics

21/03/2023 20:24

* Heron Therapeutics Inc  HRTX.OQ   HRTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 23. 
    * The San Diego California-based  company is expected to
report  a
30.2% increase in revenue to $26.898 million from $20.66 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Heron Therapeutics
Inc is
for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Heron
Therapeutics Inc is $10.5​, above​ its last closing price
of $2.08. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.38       -0.38      -0.38     Met     -1.1
 Jun. 30 2022  -0.53       -0.50      -0.55     Missed  -8.9
 Mar. 31 2022  -0.49       -0.48      -0.63     Missed  -32.4​
 Dec. 31 2021  -0.58       -0.58      -0.54     Beat    6.3
 ​​Sep.        -0.61       -0.61      -0.51     Beat    16.1
 30 2021                                                
 Jun. 30 2021  -0.52       -0.55      -0.62     Missed  -11.9​
 Mar. 31 2021  -0.58       -0.57      -0.58     Missed  -1.8
 Dec. 31 2020  -0.64       -0.65      -0.68     Missed  -4.6
 This summary was machine generated March 21 at 20:23 GMT.  All
figures in US dollars  unless otherwise stated